Background: Massive haemoptysis is a rare symptom ofcoronavirus disease 2019 (COVID-19). Management can be very challenging due to the lack of clear recommendations.
Case Description: We report a case of massive recurrent haemoptysis in a young patient who tested positive for COVID-19 with successful management using endovascular embolization.
Discussion: Life-threatening massive haemoptysis has rarely been reported as the only manifestation of COVID-19. Embolisation was the therapeutic option chosen to manage this emergency.
Learning Points: Haemoptysis is a rare atypical presentation that can reveal COVID-19, highlighting the complexity of its pathogenesis.Atypical manifestations should raise suspicion for COVID-19.In this patient with COVID-19, life-threatening massive haemoptysis was successfully treated with endovascular embolisation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451510 | PMC |
http://dx.doi.org/10.12890/2022_003475 | DOI Listing |
Lung
January 2025
Department of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, 317000, Zhejiang, China.
Objective: This integrative review aims to evaluate the efficacy and safety of nebulized tranexamic acid (TXA) in managing hemoptysis, assessing its potential as a non-invasive alternative to traditional invasive procedures.
Methods: An integrative review was conducted in accordance with PRISMA guidelines and was registered on PROSPERO (CRD42024584812). The search included databases such as PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials, encompassing studies published up to August 7, 2024.
Ann Thorac Surg Short Rep
December 2024
Department of Cardiovascular Surgery, Iwaki City Medical Center, Iwaki, Japan.
A 90-year-old man received a diagnosis of ascending aortic pseudoaneurysms after transcatheter aortic valve implantation (TAVI) using an Evolut PRO valve (Medtronic). Plug closure of the pseudoaneurysms was successfully performed, and the symptoms improved after the procedure. However, on postoperative day 4, the patient experienced sudden massive hemoptysis and died.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Respiratory, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China.
Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated chronic fibro-inflammatory condition, that can involve multiple systems. Immunoglobulin G4-related respiratory disease (IgG4-RRD) is relatively rare, with non-specific clinical symptoms. Hemoptysis is a rare clinical symptom of IgG4-RRD, and cases of massive hemoptysis in adults have not been reported.
View Article and Find Full Text PDFCureus
November 2024
Intensive Care Unit, Hospital Vila Franca de Xira, Vila Franca de Xira, PRT.
Massive hemoptysis is a life-threatening condition. Bronchial artery embolization (BAE) is an effective technique for controlling bleeding in cases of severe hemoptysis, with infrequent complications. While rare, spinal cord infarction is a serious potential complication of BAE.
View Article and Find Full Text PDFRespirol Case Rep
December 2024
Department of Pulmonary Medicine St. John's National Academy of Health Sciences Bengaluru India.
Pulmonary artery aneurysmal rupture is a rare cause of massive hemoptysis. When the suspected origin of bleeding is the pulmonary artery, comprehensive evaluation is necessary to determine aetiology and guide appropriate management. Behçet's disease and Hughes-Stovin Syndrome (HSS) are important differentials to consider after infections and malignancy have been ruled out.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!